[Elsevier/Sciencedirect] Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial

 关闭 求助已关闭
苇间风25 发表于 2026-9-10 15:20:17 | 显示全部楼层 |阅读模式
悬赏30积分


DOI号: 10.1016/S0140-6736(26)00968-2

文献链接: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00968-2/abstract

文献作者: Prof Anwen Xiong, MD[url=]a[/url],[url=]*[/url] ∙ Prof Wenxiu Yao, MD[url=]b[/url],[url=]*[/url] ∙ Prof Wei Zheng, MD[url=]c[/url],[url=]*[/url] ∙ Yan Yu[url=]*[/url] ∙ Peng Chen, MD[url=]e[/url],[url=]*[/url] ∙ Prof Hua Zhong, MD[url=]f[/url],[url=]*[/url] ∙ Junyou Ge, PhD[url=]g[/url],[url=]*[/url],[url=]†[/url] ∙ Prof Hui Wang, MD[url=]h[/url] ∙ Prof Bolin Chen, MD[url=]i[/url] ∙ Prof Haiyong Wang, MD[url=]j[/url] ∙ Prof Yun Fan, MD[url=]k[/url] ∙ Prof Yunpeng Yang, MD[url=]l[/url] ∙ Prof Xingxiang Pu, MD[url=]m[/url] ∙ Prof Xia Song, MSc[url=]n[/url] ∙ Prof Qiming Wang, MD[url=]o[/url] ∙ Prof Xiaobo Du, MD[url=]p[/url] ∙ Zhangzhou Huang, BAC[url=]q[/url] ∙ Prof Xingya Li, MD[url=]r[/url] ∙ Hui Luo, MSc[url=]s[/url] ∙ Prof Yu Yao, PhD[url=]d[/url],[url=]t[/url] ∙ Prof Qitao Yu, BAC[url=]u[/url] ∙ Prof Cuiyun Su, MSc[url=]u[/url] ∙ Prof Lang He, MD[url=]v[/url] ∙ Prof Guanming Jiang, BAC[url=]w[/url] ∙ Jiuwei Cui, MD[url=]x[/url] ∙ Prof Chunling Liu, MSc[url=]y[/url] ∙ Prof Tienan Yi, MSc[url=]z[/url] ∙ Prof Guowei Che, MD[url=]aa[/url] ∙ Prof Zhentian Liu, MSc[url=]ab[/url] ∙ Prof Lemeng Zhang, PhD[url=]ac[/url] ∙ Prof Ming Zhou, MSc[url=]ad[/url] ∙ Prof Yong Fang, MD[url=]ae[/url] ∙ Youneng Wei, MD[url=]af[/url] ∙ Yan Qing, PhD[url=]af[/url] ∙ Xiaoping Jin, PhD[url=]af[/url] ∙ Prof Caicun Zhou, MD

备注信息:

已采纳

附件内容

查看完整内容

全部回复1 显示全部楼层
T-Mac麦蒂 发表于 2026-9-10 15:20:18 | 显示全部楼层

当前求助已完成,请重新发起求助。

已完结状态的附件将会在24小时内删除。
VIP会员
  • 发布

  • 回复

  • 积分

    830

返回列表